Unusual options activity in #$RVMD. Money on both sides, which usually means traders expect a move but don't agree on the direction.
Start a free 7-day trial
#optionsflow #stocks
Start a free 7-day trial
#optionsflow #stocks
RVMD Technical Levels: Options Flow Mixed Between $189 and $197
RVMD at $192.28: support $189.16, resistance $196.88; the chart, options flow and dark pools are mixed.
globaltradersacademy.com
November 8, 2026 at 5:29 PM
Unusual options activity in #$RVMD. Money on both sides, which usually means traders expect a move but don't agree on the direction.
Start a free 7-day trial
#optionsflow #stocks
Start a free 7-day trial
#optionsflow #stocks
Revolution Medicines ($RVMD) – 13G holder update
• Holder: FMR LLC
• Stake: now 7.2% (about $3.1B)
• SEC Filing: Schedule 13G/A
• Filing Date: November 5, 2026
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: FMR LLC
• Stake: now 7.2% (about $3.1B)
• SEC Filing: Schedule 13G/A
• Filing Date: November 5, 2026
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
FMR LLC: 7.2% of Revolution Medicines ($RVMD)
Schedule 13G/A filed Nov 5. Who filed, the stake, and how it changed.
elixstocks.com
November 5, 2026 at 9:43 PM
Revolution Medicines ($RVMD) – 13G holder update
• Holder: FMR LLC
• Stake: now 7.2% (about $3.1B)
• SEC Filing: Schedule 13G/A
• Filing Date: November 5, 2026
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: FMR LLC
• Stake: now 7.2% (about $3.1B)
• SEC Filing: Schedule 13G/A
• Filing Date: November 5, 2026
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
Investment Analysts’ Weekly Ratings Changes for Revolution Medicines (RVMD)
A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD): 11/6/2026 – Revolution Medicines had its price target raised by HC Wainwright from…
A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD): 11/6/2026 – Revolution Medicines had its price target raised by HC Wainwright from…
Investment Analysts’ Weekly Ratings Changes for Revolution Medicines (RVMD)
A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD): 11/6/2026 – Revolution Medicines had its price target raised by HC Wainwright from…
news-area.com
November 7, 2026 at 7:58 AM
Investment Analysts’ Weekly Ratings Changes for Revolution Medicines (RVMD)
A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD): 11/6/2026 – Revolution Medicines had its price target raised by HC Wainwright from…
A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD): 11/6/2026 – Revolution Medicines had its price target raised by HC Wainwright from…
#BiotechHangout: Brian Skorney, Adam Feuerstein, Paul Matteis, Yaron Werber on election results, company news: #$VRTX pove, #$RVMD Rasonque, #$NBIX Vykat, #$MDGL whistleblower, Usona/$CMPS, #$SNY stops #$NRIX STAT6 degrader, #$NVS Zolgensma, earnings: #$AMGN, #$ONC, data: #AHA26 & #ASH26 bit.ly/3Wu4F3c
November 6, 2026 at 2:01 PM
#BiotechHangout: Brian Skorney, Adam Feuerstein, Paul Matteis, Yaron Werber on election results, company news: #$VRTX pove, #$RVMD Rasonque, #$NBIX Vykat, #$MDGL whistleblower, Usona/$CMPS, #$SNY stops #$NRIX STAT6 degrader, #$NVS Zolgensma, earnings: #$AMGN, #$ONC, data: #AHA26 & #ASH26 bit.ly/3Wu4F3c
🟢 #$RVMD — Regulatory Designation
FDA Orphan Drug Designation for Zoldonrasib in Pancreatic Cancer
FDA granted Orphan Drug Designation to zoldonrasib for pancreatic cancer. Fifth ODD across the RAS(ON) inhibitor portfolio.
https://biostock.app/symbols/RVMD
FDA Orphan Drug Designation for Zoldonrasib in Pancreatic Cancer
FDA granted Orphan Drug Designation to zoldonrasib for pancreatic cancer. Fifth ODD across the RAS(ON) inhibitor portfolio.
https://biostock.app/symbols/RVMD
November 4, 2026 at 11:31 PM
🟢 #$RVMD — Regulatory Designation
FDA Orphan Drug Designation for Zoldonrasib in Pancreatic Cancer
FDA granted Orphan Drug Designation to zoldonrasib for pancreatic cancer. Fifth ODD across the RAS(ON) inhibitor portfolio.
https://biostock.app/symbols/RVMD
FDA Orphan Drug Designation for Zoldonrasib in Pancreatic Cancer
FDA granted Orphan Drug Designation to zoldonrasib for pancreatic cancer. Fifth ODD across the RAS(ON) inhibitor portfolio.
https://biostock.app/symbols/RVMD
🟢 #$RVMD — Regulatory Designation
FDA Breakthrough Therapy Designation for Daraxonrasib + Gemcitabine/Nab-Paclitaxel in Treatment-Naive Metastatic PDAC
FDA granted BTD for daraxonrasib combined with gemcitabine and nab-paclitaxel in treatment-naive metastatic p…
https://biostock.app/symbols/RVMD
FDA Breakthrough Therapy Designation for Daraxonrasib + Gemcitabine/Nab-Paclitaxel in Treatment-Naive Metastatic PDAC
FDA granted BTD for daraxonrasib combined with gemcitabine and nab-paclitaxel in treatment-naive metastatic p…
https://biostock.app/symbols/RVMD
November 4, 2026 at 11:31 PM
🟢 #$RVMD — Regulatory Designation
FDA Breakthrough Therapy Designation for Daraxonrasib + Gemcitabine/Nab-Paclitaxel in Treatment-Naive Metastatic PDAC
FDA granted BTD for daraxonrasib combined with gemcitabine and nab-paclitaxel in treatment-naive metastatic p…
https://biostock.app/symbols/RVMD
FDA Breakthrough Therapy Designation for Daraxonrasib + Gemcitabine/Nab-Paclitaxel in Treatment-Naive Metastatic PDAC
FDA granted BTD for daraxonrasib combined with gemcitabine and nab-paclitaxel in treatment-naive metastatic p…
https://biostock.app/symbols/RVMD
Revolution Medicines $RVMD reported Q3 2026 EPS of -$1.90, beating the -$2.37 estimate by 19.8%. Revenue of $197.6M beat the $27.6M estimate by 617.0%.
https://fundspec.ai/s/RVMD/earnings
Build and train your own AI trading models right on your phone. No code required.
https://fundspec.ai/s/RVMD/earnings
Build and train your own AI trading models right on your phone. No code required.
November 4, 2026 at 9:12 PM
Revolution Medicines $RVMD reported Q3 2026 EPS of -$1.90, beating the -$2.37 estimate by 19.8%. Revenue of $197.6M beat the $27.6M estimate by 617.0%.
https://fundspec.ai/s/RVMD/earnings
Build and train your own AI trading models right on your phone. No code required.
https://fundspec.ai/s/RVMD/earnings
Build and train your own AI trading models right on your phone. No code required.
#$RVMD -7%: New pancreatic drug hit $198M in 5 wks but sales may slow + high spending. #$VCYT -56%: Rev +15% but key test volumes missed; growth cut. #$ARQT -23%: Zoryve +45%, guidance up, profits missed on higher costs. #$EWTX: FDA OK for HCM drug; Phase 3 starts Q4 2026. notreload.xyz/wall-street-...
November 5, 2026 at 5:52 PM
#$RVMD -7%: New pancreatic drug hit $198M in 5 wks but sales may slow + high spending. #$VCYT -56%: Rev +15% but key test volumes missed; growth cut. #$ARQT -23%: Zoryve +45%, guidance up, profits missed on higher costs. #$EWTX: FDA OK for HCM drug; Phase 3 starts Q4 2026. notreload.xyz/wall-street-...
#RVMD Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
https://www.stocktitan.net/news/RVMD/revolution-medicines-reports-third-quarter-2026-financial-results-i7oe494slqyu.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RVMD/revolution-medicines-reports-third-quarter-2026-financial-results-i7oe494slqyu.html?utm_source=stocktitan-bluesky&utm_medium=social
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 9:02 PM
#RVMD Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
https://www.stocktitan.net/news/RVMD/revolution-medicines-reports-third-quarter-2026-financial-results-i7oe494slqyu.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RVMD/revolution-medicines-reports-third-quarter-2026-financial-results-i7oe494slqyu.html?utm_source=stocktitan-bluesky&utm_medium=social
Gain porn, large-cap edition. Furthest above their 52-week low:
1. SNDK — +356%
2. MU — +258%
3. RVMD — +213%
Hindsight is the best-performing strategy on record. Full board + the math 👇
1. SNDK — +356%
2. MU — +258%
3. RVMD — +213%
Hindsight is the best-performing strategy on record. Full board + the math 👇
November 8, 2026 at 4:06 PM
Gain porn, large-cap edition. Furthest above their 52-week low:
1. SNDK — +356%
2. MU — +258%
3. RVMD — +213%
Hindsight is the best-performing strategy on record. Full board + the math 👇
1. SNDK — +356%
2. MU — +258%
3. RVMD — +213%
Hindsight is the best-performing strategy on record. Full board + the math 👇
🏢 RVMD Revolution Medicines · 💵 EPS ✅ beat · 💰 Rev ✅ beat
⏳ Not in yet: Warner Bros Discovery (WBD), Arm Holdings (ARM)
🔒 Numbers & expected moves → Whisper (Pro)
Did APP's numbers surprise you? Tell us below 💬
⏳ Not in yet: Warner Bros Discovery (WBD), Arm Holdings (ARM)
🔒 Numbers & expected moves → Whisper (Pro)
Did APP's numbers surprise you? Tell us below 💬
November 4, 2026 at 11:05 PM
🏢 RVMD Revolution Medicines · 💵 EPS ✅ beat · 💰 Rev ✅ beat
⏳ Not in yet: Warner Bros Discovery (WBD), Arm Holdings (ARM)
🔒 Numbers & expected moves → Whisper (Pro)
Did APP's numbers surprise you? Tell us below 💬
⏳ Not in yet: Warner Bros Discovery (WBD), Arm Holdings (ARM)
🔒 Numbers & expected moves → Whisper (Pro)
Did APP's numbers surprise you? Tell us below 💬
🏢 QCOM Qualcomm (Q4) · 💵 EPS ❌ -0.7% · 💰 Rev ✅ +1.2%
📈 Expected ±8.3% → Actual -9.5% · ⚠️ Bigger than priced
🏢 RDW Redwire (Q3) · 💵 EPS ✅ +10.0% · 💰 Rev ❌ -14.0%
📈 Expected ±11.4% → Actual -19.8% · ⚠️ Bigger than priced
🏢 RVMD Revolution Medicines (Q3) · 💵 EPS ✅ +18.8% · 💰 Rev ✅ +724.4%
📈 Expected ±8.3% → Actual -9.5% · ⚠️ Bigger than priced
🏢 RDW Redwire (Q3) · 💵 EPS ✅ +10.0% · 💰 Rev ❌ -14.0%
📈 Expected ±11.4% → Actual -19.8% · ⚠️ Bigger than priced
🏢 RVMD Revolution Medicines (Q3) · 💵 EPS ✅ +18.8% · 💰 Rev ✅ +724.4%
November 7, 2026 at 2:07 AM
🏢 QCOM Qualcomm (Q4) · 💵 EPS ❌ -0.7% · 💰 Rev ✅ +1.2%
📈 Expected ±8.3% → Actual -9.5% · ⚠️ Bigger than priced
🏢 RDW Redwire (Q3) · 💵 EPS ✅ +10.0% · 💰 Rev ❌ -14.0%
📈 Expected ±11.4% → Actual -19.8% · ⚠️ Bigger than priced
🏢 RVMD Revolution Medicines (Q3) · 💵 EPS ✅ +18.8% · 💰 Rev ✅ +724.4%
📈 Expected ±8.3% → Actual -9.5% · ⚠️ Bigger than priced
🏢 RDW Redwire (Q3) · 💵 EPS ✅ +10.0% · 💰 Rev ❌ -14.0%
📈 Expected ±11.4% → Actual -19.8% · ⚠️ Bigger than priced
🏢 RVMD Revolution Medicines (Q3) · 💵 EPS ✅ +18.8% · 💰 Rev ✅ +724.4%
🏢 RVMD Revolution Medicines (Q3) · 🎯 🟢23 🟡1 🔴0
🔒 Numbers & expected moves → Whisper (Pro)
📲 Live market levels & updates for Pro members:
👉 Ictradex Pulse (free): https://t.me/IctradexPulse
Beat or miss for DDOG tonight? Call it below 👇
🔒 Numbers & expected moves → Whisper (Pro)
📲 Live market levels & updates for Pro members:
👉 Ictradex Pulse (free): https://t.me/IctradexPulse
Beat or miss for DDOG tonight? Call it below 👇
November 4, 2026 at 10:02 AM
🏢 RVMD Revolution Medicines (Q3) · 🎯 🟢23 🟡1 🔴0
🔒 Numbers & expected moves → Whisper (Pro)
📲 Live market levels & updates for Pro members:
👉 Ictradex Pulse (free): https://t.me/IctradexPulse
Beat or miss for DDOG tonight? Call it below 👇
🔒 Numbers & expected moves → Whisper (Pro)
📲 Live market levels & updates for Pro members:
👉 Ictradex Pulse (free): https://t.me/IctradexPulse
Beat or miss for DDOG tonight? Call it below 👇
🏢 UBER Uber · 💵 EPS ❌ miss · 💰 Rev ❌ miss
🏢 UTHR United Therapeutics · 💵 EPS ❌ miss · 💰 Rev ✅ beat
⏳ Later today: Warner Bros Discovery (WBD), AppLovin (APP), Arm Holdings (ARM), McKesson (MCK), MercadoLibre (MELI), Qualcomm (QCOM), Redwire (RDW), Revolution Medicines (RVMD)
🏢 UTHR United Therapeutics · 💵 EPS ❌ miss · 💰 Rev ✅ beat
⏳ Later today: Warner Bros Discovery (WBD), AppLovin (APP), Arm Holdings (ARM), McKesson (MCK), MercadoLibre (MELI), Qualcomm (QCOM), Redwire (RDW), Revolution Medicines (RVMD)
November 4, 2026 at 3:02 PM
🏢 UBER Uber · 💵 EPS ❌ miss · 💰 Rev ❌ miss
🏢 UTHR United Therapeutics · 💵 EPS ❌ miss · 💰 Rev ✅ beat
⏳ Later today: Warner Bros Discovery (WBD), AppLovin (APP), Arm Holdings (ARM), McKesson (MCK), MercadoLibre (MELI), Qualcomm (QCOM), Redwire (RDW), Revolution Medicines (RVMD)
🏢 UTHR United Therapeutics · 💵 EPS ❌ miss · 💰 Rev ✅ beat
⏳ Later today: Warner Bros Discovery (WBD), AppLovin (APP), Arm Holdings (ARM), McKesson (MCK), MercadoLibre (MELI), Qualcomm (QCOM), Redwire (RDW), Revolution Medicines (RVMD)
#$RVMD · Revolution Medicines reported third-quarter 2026 results
Revolution Medicines announced its financial results for the third quarter of 2026. It reported $197.6 million in net product revenue for RASONQUE and a net loss of $407.5 million. These are the company's first…
#stocks #investing
Revolution Medicines announced its financial results for the third quarter of 2026. It reported $197.6 million in net product revenue for RASONQUE and a net loss of $407.5 million. These are the company's first…
#stocks #investing
Revolution Medicines reported third-quarter 2026 results
Revolution Medicines announced its financial results for the third quarter of 2026. It reported $197.6 million in net product revenue for RASONQUE and a net loss of $407.5 million. These are the company's first quarterly figures since receiving FDA approval for RASONQUE in late August 2026.
insiderpost.org
November 5, 2026 at 11:11 AM
#$RVMD · Revolution Medicines reported third-quarter 2026 results
Revolution Medicines announced its financial results for the third quarter of 2026. It reported $197.6 million in net product revenue for RASONQUE and a net loss of $407.5 million. These are the company's first…
#stocks #investing
Revolution Medicines announced its financial results for the third quarter of 2026. It reported $197.6 million in net product revenue for RASONQUE and a net loss of $407.5 million. These are the company's first…
#stocks #investing
Revolution Medicines ($RVMD) – New 13G stake
• Holder: Vanguard Capital Management
• Stake: 0 → 5.13% (about $2.1B)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: Vanguard Capital Management
• Stake: 0 → 5.13% (about $2.1B)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
Vanguard Capital Management LLC: 5.13% of Revolution Medicines ($RVMD)
Filed Oct 30. Who filed, the stake, and how it changed.
elixstocks.com
October 30, 2026 at 7:09 PM
Revolution Medicines ($RVMD) – New 13G stake
• Holder: Vanguard Capital Management
• Stake: 0 → 5.13% (about $2.1B)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: Vanguard Capital Management
• Stake: 0 → 5.13% (about $2.1B)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
🏢 MCK McKesson (Q2) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢11 🟡3 🔴0
🏢 QCOM Qualcomm (Q4) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢2 🟡6 🔴2
🏢 RVMD Revolution Medicines (Q3) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢23 🟡1 🔴0
📊 🎯 🟢11 🟡3 🔴0
🏢 QCOM Qualcomm (Q4) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢2 🟡6 🔴2
🏢 RVMD Revolution Medicines (Q3) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢23 🟡1 🔴0
November 1, 2026 at 12:06 PM
🏢 MCK McKesson (Q2) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢11 🟡3 🔴0
🏢 QCOM Qualcomm (Q4) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢2 🟡6 🔴2
🏢 RVMD Revolution Medicines (Q3) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢23 🟡1 🔴0
📊 🎯 🟢11 🟡3 🔴0
🏢 QCOM Qualcomm (Q4) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢2 🟡6 🔴2
🏢 RVMD Revolution Medicines (Q3) · 🌙 16:00 ET · 21:00 UTC · Thu 05:00 SGT
📊 🎯 🟢23 🟡1 🔴0
Revolution Medicines (RVMD) Expected to Announce Quarterly Earnings on Wednesday
Revolution Medicines (NASDAQ:RVMD – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of…
Revolution Medicines (NASDAQ:RVMD – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of…
Revolution Medicines (RVMD) Expected to Announce Quarterly Earnings on Wednesday
Revolution Medicines (NASDAQ:RVMD – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of…
news-area.com
October 28, 2026 at 10:59 PM
Revolution Medicines (RVMD) Expected to Announce Quarterly Earnings on Wednesday
Revolution Medicines (NASDAQ:RVMD – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of…
Revolution Medicines (NASDAQ:RVMD – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of…
Tango's updated pancreatic cancer data gets chilly market reception #$TNGX #$RVMD #ESMO26 firstwordpharma.com/story/8258483
October 24, 2026 at 3:29 AM
Tango's updated pancreatic cancer data gets chilly market reception #$TNGX #$RVMD #ESMO26 firstwordpharma.com/story/8258483
#RVMD Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Me…
https://www.stocktitan.net/news/RVMD/revolution-medicines-presents-overall-survival-data-for-rasonquetm-c9oplyfw94l9.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RVMD/revolution-medicines-presents-overall-survival-data-for-rasonquetm-c9oplyfw94l9.html?utm_source=stocktitan-bluesky&utm_medium=social
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 23, 2026 at 11:30 AM
#RVMD Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Me…
https://www.stocktitan.net/news/RVMD/revolution-medicines-presents-overall-survival-data-for-rasonquetm-c9oplyfw94l9.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RVMD/revolution-medicines-presents-overall-survival-data-for-rasonquetm-c9oplyfw94l9.html?utm_source=stocktitan-bluesky&utm_medium=social
#RVMD Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
https://www.stocktitan.net/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-rchavv0qu74l.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-rchavv0qu74l.html?utm_source=stocktitan-bluesky&utm_medium=social
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Revolution Medicines (RVMD) will report third-quarter 2026 financial results after market close on November 4, 2026. Senior management will host a webcast at 4:30 p.m. ET that day to discuss the results and provide an update on corporate progress. A replay will be available on the company’s website for at least 14 days.
www.stocktitan.net
October 21, 2026 at 8:05 PM
#RVMD Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
https://www.stocktitan.net/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-rchavv0qu74l.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-rchavv0qu74l.html?utm_source=stocktitan-bluesky&utm_medium=social